SCHEMBL11953262

SCHEMBL11953262

Cc1cccc(C)c1OCC(C)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN4A P35499 10/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2D6 P10635 2/20 0.49
NFKB1 P19838 2/20 0.49
THPO P40225 1/20 0.49
LMNA P02545 2/20 0.48
SCN1A P35498 2/20 0.48
SCN5A Q14524 2/20 0.48
SCN9A Q15858 2/20 0.48
TSHR P16473 2/20 0.48
KCNH2 Q12809 2/20 0.48
CYP2C9 P11712 1/20 0.48
KCNK3 O14649 1/20 0.48
CACNA1F O60840 1/20 0.48
KCNK2 O95069 1/20 0.48
GBA1 P04062 1/20 0.48
MAOA P21397 1/20 0.48
HTR2A P28223 1/20 0.48
SLC6A4 P31645 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11965216 1.00 SCN4A (0.49) SCN4ACYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL11953260 0.94 SCN4A (0.55) SCN4ACYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL10254239 0.94 SCN4A (0.55) SCN4ACYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL17437597 0.94 SCN4A (0.55) SCN4ACYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL10258210 0.88 CNR1 (0.46) SCN4ACYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL17437456 0.79 SCN9A (0.55) SCN4ACYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL17437555 0.79 SCN9A (0.55) SCN4ACYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL10255593 0.78 SCN4A (0.50) SCN4ACYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL10255201 0.78 SCN4A (0.54) SCN4ACYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL21834932 0.77 SCN4A (0.54) SCN4ACYP1A2CYP3A4CYP2D6NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120196933-A1 MEXILETINE PRODRUGS FRANKLIN RICHARD (GB) 2012-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196933-A1 MEXILETINE PRODRUGS SLC16A1, MTPN, SLC16A3 SCN4A 88/4885CYP1A2 773/4885CYP3A4 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.